Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients
- PMID: 12133625
- DOI: 10.1016/s0022-1759(02)00104-7
Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients
Abstract
The major goal of therapeutic cancer vaccine trials is to mediate tumor regression. However, it is critically important to devise in vitro immunological assays that correlate with clinical outcome, for use as surrogate markers of vaccine efficacy. To date, clinical emphasis has been placed on peptide vaccines, but trends towards the use of more complex immunogens such as whole proteins require the development of efficient and sensitive methods for monitoring their immunological effects. In the context of a vaccination trial using full-length tyrosinase (Ty) to immunize patients with metastatic melanoma, a monitoring technique was developed in which autologous dendritic cells (DC) infected with a recombinant adenovirus encoding the Ty protein were used to assess the Ty-specific reactivity of fresh peripheral blood lymphocytes (PBL) collected from patients at different intervals during therapy. Quantitative real-time RT-PCR (qRT-PCR) was used to measure the production of cytokine mRNA by T cells following a 2.5-h incubation with Ty-expressing DC. Two out of ten patients studied demonstrated Ty protein-specific reactivity that increased during and after the period of vaccination. While one of these patients also reacted to an HLA-A1-compatible Ty peptide, the second did not recognize any of the known Ty epitopes, highlighting the importance of this technique for monitoring the effects of complex vaccines.
Similar articles
-
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.Clin Cancer Res. 2006 Apr 15;12(8):2526-37. doi: 10.1158/1078-0432.CCR-05-2061. Clin Cancer Res. 2006. PMID: 16638862 Free PMC article. Clinical Trial.
-
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23. Cancer J Sci Am. 1998. PMID: 9815296 Clinical Trial.
-
Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma.Int J Cancer. 1999 Jan 5;80(1):39-43. doi: 10.1002/(sici)1097-0215(19990105)80:1<39::aid-ijc8>3.0.co;2-y. Int J Cancer. 1999. PMID: 9935227 Clinical Trial.
-
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.Dan Med J. 2013 Dec;60(12):B4774. Dan Med J. 2013. PMID: 24355457 Review.
-
The role of quantitative PCR for the immune monitoring of cancer patients.Expert Opin Biol Ther. 2002 Jun;2(5):557-64. doi: 10.1517/14712598.2.5.557. Expert Opin Biol Ther. 2002. PMID: 12079490 Review.
Cited by
-
Immunomodulatory effects of polysaccharide from marine fungus Phoma herbarum YS4108 on T cells and dendritic cells.Mediators Inflamm. 2014;2014:738631. doi: 10.1155/2014/738631. Epub 2014 Nov 30. Mediators Inflamm. 2014. PMID: 25525304 Free PMC article.
-
CyProQuant-PCR: a real time RT-PCR technique for profiling human cytokines, based on external RNA standards, readily automatable for clinical use.BMC Immunol. 2005 Mar 4;6:5. doi: 10.1186/1471-2172-6-5. BMC Immunol. 2005. PMID: 15748278 Free PMC article.
-
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.Clin Cancer Res. 2006 Apr 15;12(8):2526-37. doi: 10.1158/1078-0432.CCR-05-2061. Clin Cancer Res. 2006. PMID: 16638862 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials